Literature DB >> 27037816

Prevalence of liver fluke infection in Irish horses and assessment of a serological test for diagnosis of equine fasciolosis.

A Quigley1, M Sekiya1, S Egan1, A Wolfe1, C Negredo1, G Mulcahy1.   

Abstract

BACKGROUND: There is little information on the prevalence of Fasciola hepatica infection in the horse population in Ireland or the potential impact of fluke infection on animal health.
OBJECTIVES: To investigate F. hepatica infection in the Irish horse population and to assess the diagnostic potential of an indirect enzyme-linked immunosorbent assay (ELISA) based on the F. hepatica recombinant cathepsin L1 (CL1) antigen. STUDY
DESIGN: Cross-sectional abattoir survey of horses for liver fluke status.
METHODS: Animals (n = 200) were examined at an abattoir between May 2013 and April 2014. Horses were graded ante mortem for body condition score. Blood and faeces were collected and livers were examined post mortem by gross morphology. A cohort (n = 35) of livers were also examined histologically. Haematology and blood biochemistry, including serum liver enzyme activities, were measured and faeces were sedimented for egg counts. Serum was assayed by indirect ELISA using a recombinant CL1.
RESULTS: The prevalence of liver fluke infection was 9.5%. There was no correlation between liver fluke status and time of year, breed classification, age group, sex, body condition score, ante mortem assessment, strongyle infection status, serum liver enzyme activities or CL1 concentration. A comparison of the CL1 ELISA in horse sera compared with a reference standard diagnosis showed high specificity of 95.6% (95% confidence interval [CI] 91.5-98.0%), but low sensitivity of 42.1% (95% CI 20.2-66.5%). MAIN LIMITATIONS: This study is limited by its nature as an abattoir study, the relatively small number of animals examined (n = 200), and the absence of a known negative group of horses.
CONCLUSIONS: Blood biomarkers are not good indicators of liver fluke infection and the CL1 ELISA is not a sensitive tool for diagnosis of fluke infection in the horse. The prevalence of F. hepatica in horses indicates that further research is required to assess the potential impact of liver fluke on equine liver health.
© 2016 EVJ Ltd.

Entities:  

Keywords:  zzm321990Fasciola hepaticazzm321990; ELISA; horse; liver fluke

Mesh:

Year:  2016        PMID: 27037816     DOI: 10.1111/evj.12577

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  5 in total

1.  The prevalence and risk factors of liver fluke infection in Mexican horses, donkeys and mules in tropical and temperate regions.

Authors:  Abel Villa-Mancera; Alejandro Reynoso-Palomar
Journal:  Parasitol Res       Date:  2020-10-02       Impact factor: 2.289

2.  Molecular Characterization of Fasciola spp. from a Donkey (Equus asinus) Using Partial Sequencing of cox1 and nad1.

Authors:  Mohammad Asadpour; Hassan Sharifiyazdi; Mohammad Moazeni; Seyed Hossein Malekpour
Journal:  Iran J Parasitol       Date:  2020 Oct-Dec       Impact factor: 1.012

3.  Fasciola hepatica in UK horses.

Authors:  A K Howell; F Malalana; N J Beesley; J E Hodgkinson; H Rhodes; M Sekiya; D Archer; H E Clough; P Gilmore; D J L Williams
Journal:  Equine Vet J       Date:  2019-07-21       Impact factor: 2.888

4.  Liver fluke in Irish sheep: prevalence and associations with management practices and co-infection with rumen fluke.

Authors:  Maria Pia Munita; Rosemary Rea; Ana Maria Martinez-Ibeas; Noel Byrne; Guy McGrath; Luis Enrique Munita-Corbalan; Mary Sekiya; Grace Mulcahy; Ríona G Sayers
Journal:  Parasit Vectors       Date:  2019-11-06       Impact factor: 3.876

5.  Timing of Transcriptomic Peripheral Blood Mononuclear Cell Responses of Sheep to Fasciola hepatica Infection Differs From Those of Cattle, Reflecting Different Disease Phenotypes.

Authors:  Dagmara A Niedziela; Amalia Naranjo-Lucena; Verónica Molina-Hernández; John A Browne; Álvaro Martínez-Moreno; José Pérez; David E MacHugh; Grace Mulcahy
Journal:  Front Immunol       Date:  2021-09-20       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.